InternationalUSRemember you can easily switch between MIP US and MIP International at any time

What's on this week

Managing Intellectual Property


Managing IP lists the IP meetings, decisions and events taking place this week

Monday May 21

Hearing begins in Samsung Electronics (UK) Limited and Anr v Apple Inc at the Court of Appeal in London.

WIPO’s Standing Committee on the Law of Patents (eighteenth session) meets from Monday to Friday in Geneva.

OHIM hosts the 7th Trade Marks Liaison meeting between OHIM officials and representatives of EU national IP offices in Alicante.

The Korean...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Graphics showing what patent protection will cost in Europe, post- #unitarypatent ($/trial) http://t.co/EClJx919gW http://t.co/GBc0XfX2yz

Jul 3 2015 02:28 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @The_IPO: Do you work in #mediarelations or know someone who does? @The_IPO have a vacancy in our #London office http://t.co/SkHPfN2yIY

Jul 3 2015 01:48 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @OAMITWEETS: Our webinar programme for July 7 http://t.co/CbPXRi0ITB

Jul 3 2015 11:45 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements